|Day Low/High||24.80 / 25.35|
|52 Wk Low/High||19.94 / 28.53|
Quest and IBM are rolling out a genomic sequencing service powered by Big Blue's Watson supercomputer.
All-in-One library prep kit, plus collection, stabilization and bioinformatics solutions enable NIPT and cancer research
Partnering with Hamilton Robotics to deliver automated workflows for DNA fingerprinting
Proposal would adjust capital structure through 4% reduction in number of shares outstanding and direct capital repayment to shareholders
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AEUA, BPMC, CAA, CAT, COMM, DAIO, DKS, EFII, HDS, HOG, ISTR, KEM, MSCC, MT, NWHM, QGEN, QLYS, TPRE Downgrades: COHU, DMD, EMN, GRC, SFS, SYNA, WWE Initiations: None Read on to get TheStreet Quant Ratings' detailed report:
TheStreet highlights 3 stocks pushing the diversified services industry higher today.
Qiagen (QGEN) stock is jumping on Friday morning after the company posted earnings and revenue that topped analysts’ projections for the 2016 second quarter.
Trade-Ideas LLC identified Qiagen (QGEN) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate
QIAseq Targeted NGS panels deliver highly sensitive, unbiased and accurate NGS insights
These five technical setups are showing solid upside potential right now.
Transaction will enhance leadership position in RNA solutions from Sample to Insight
Ever hear of space congestion, Bots or liquid biopsy? The phrases are part of a group of 21 investment buzzwords identified by Goldman Sachs in its annual buzzword report.
Project that measured pathogens in New York City subways goes global this summer
New follow-up assay helps stratify patients with transforming HPV infections
Acceptance rate lowered to 89.20% of share capital and voting rights to reflect possible effect of warrants
Offer for DKK 18 per share remains valid until 20 June 2016
Key opinion leaders' expertise to guide design of new gene panels for GeneReader NGS
Actionable Insights Tumor Panel enables monitoring of cancer biomarkers from plasma samples
Reference data set from Horizon affirms proven accuracy of GeneReader workflow
Collaboration with Therawis addresses unmet need to guide clinical decisions in breast cancer
Trade-Ideas LLC identified Qiagen (QGEN) as a weak on high relative volume candidate
Offer for DKK 18 per share remains valid until 2 June 2016